This article is reproduced from the 97th issue of “Ganoderma” magazine in 2023, published with author’s permission. All rights to this article belong to the author.
A significant difference can be observed in the brain between a healthy individual (غادر) and an Alzheimer’s disease patient (right).
(Image source: Wikimedia Commons)
Alzheimer’s disease (AD), commonly known as senile dementia, is a progressive neurodegenerative disorder characterized by age-related cognitive impairment and memory loss. With the increase in human lifespan and population aging, the prevalence of Alzheimer’s disease is steadily rising, posing a significant burden on families and society. لذلك, exploring multiple approaches to prevent and treat Alzheimer’s disease has become a topic of great research interest.
In my article titled “Exploring the Research on الجانوديرما for Preventing and Treating Alzheimer’s Disease,” published in the 83rd issue of “Ganoderma” magazine in 2019, I introduced the pathogenesis of Alzheimer’s disease and the pharmacological effects of غانوديرما لوكيدوم in preventing and treating Alzheimer’s disease. Specifically, غانوديرما لوكيدوم extracts, غانوديرما لوكيدوم السكريات, غانوديرما لوكيدوم triterpenes, و غانوديرما لوكيدوم spore powder were found to improve learning and memory impairments in Alzheimer’s disease rat models. These components also exhibited protective effects against degenerative neuropathological changes in the hippocampal brain tissue of the Alzheimer’s disease rat models, reduced neuroinflammation in brain tissues, increased the activity of superoxide dismutase (SOD) in the hippocampal brain tissue, decreased the levels of malondialdehyde (MDA) as an oxidative product, and demonstrated preventive and therapeutic effects in experimental animal models of Alzheimer’s disease.
The two preliminary clinical studies on غانوديرما لوكيدوم for preventing and treating Alzheimer’s disease, introduced in the article, have not definitively confirmed the effectiveness of غانوديرما لوكيدوم in Alzheimer’s disease. لكن, combined with numerous promising pharmacological research findings, they provide hope for further clinical studies.
The effect of usingغانوديرما لوكيدوم spore powder alone to treat Alzheimer’s disease is not obvious.
Reviewing the research paper titled “Spore powder of غانوديرما لوكيدوم for the treatment of Alzheimer’s disease: A pilot study” published in the journal “Medicine” [1], the authors randomly divided 42 patients who met the diagnostic criteria for Alzheimer’s disease into an experimental group and a control group, مع 21 patients in each group. The experimental group received oral administration of غانوديرما لوكيدوم spore powder capsules (SPGL group) at a dosage of 4 capsules (250 mg each capsule) three times a day while the control group only received placebo capsules. Both groups underwent a 6-week treatment.
At the end of the treatment, compared to the control group, the SPGL group showed a reduction in scores for the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI), indicating an improvement in cognitive and behavioral impairments, but the differences were not statistically significant (طاولة 1). The World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire showed an increase in life quality scores, indicating an improvement in life quality, but again, the differences were not statistically significant (طاولة 2). Both groups experienced mild adverse reactions, with no significant differences.
The authors of the paper believe that the treatment of Alzheimer’s disease with غانوديرما لوكيدوم spore powder capsules for 6 weeks did not show significant therapeutic effects, possibly due to the short duration of treatment. Future clinical trials with large sample sizes and longer treatment durations are needed to gain a clearer understanding of the clinical efficacy of غانوديرما لوكيدوم spore powder capsules in the treatment of Alzheimer’s disease.
The combined use ofغانوديرما لوكيدوم spore powder with conventional treatment drugs significantly improves the therapeutic efficacy in treating Alzheimer’s disease.
حديثاً, a study evaluated the combined effects of غانوديرما لوكيدوم spore powder and the Alzheimer’s disease medication memantine on cognition and quality of life in patients with mild to moderate Alzheimer’s disease [2]. Forty-eight patients diagnosed with Alzheimer’s disease, aged 50 ل 86 years, were randomly divided into a control group and an experimental group, مع 24 patients in each group (n=24).
Prior to treatment, there were no statistically significant differences between the two groups in terms of gender, dementia degree, ADAS-cog, NPI, and WHOQOL-BREF scores (P>0.5). The control group received memantine capsules at a dose of 10 mg, twice a day, while the experimental group received the same dose of memantine along with غانوديرما لوكيدوم spore powder capsules (SPGL) at a dose of 1000 mg, three times a day. Both groups were treated for 6 weeks, and the basic data of the patients were recorded. The cognitive function and quality of life of the patients were assessed using the ADAS-cog, NPI, and WHOQOL-BREF scoring scales.
After treatment, both groups of patients showed a significant reduction in ADAS-cog and NPI scores compared to before treatment. Additionally, the experimental group had significantly lower ADAS-cog and NPI scores than the control group, with statistically significant differences (P<0.05) (طاولة 3, طاولة 4). Following treatment, both groups of patients demonstrated a significant increase in scores for physiology, psychology, social relationships, بيئة, and overall quality of life in the WHOQOL-BREF questionnaire compared to before treatment. علاوة على ذلك, the experimental group had significantly higher WHOQOL-BREF scores than the control group, with statistically significant differences (P<0.05) (طاولة 5).
Memantine, known as a novel N-methyl-D-aspartate (NMDA) receptor antagonist, can non-competitively block NMDA receptors, thereby reducing glutamic acid-induced NMDA receptor overexcitation and preventing cell apoptosis. It improves cognitive function, behavioral disorder, activities of daily living, and dementia severity in patients with Alzheimer’s disease. It is used for the treatment of mild, moderate, and severe Alzheimer’s disease. لكن, the use of this medication alone still has limited benefits for patients with Alzheimer’s disease.
The results of this study show that the combined application of غانوديرما لوكيدوم spore powder and memantine can enhance patients’ behavioral and cognitive abilities and significantly improve their quality of life.
Choosing the right medication approach is crucial for treating Alzheimer’s disease.
In the above two randomized controlled clinical trials of غانوديرما لوكيدوم spore powder for the treatment of Alzheimer’s disease, the selection of cases, diagnosis, source of Ganoderma lucidum spore powder, dosage, course of treatment, and efficacy evaluation indicators were the same, but the clinical efficacy was different. After statistical analysis, the use of غانوديرما لوكيدوم spore powder alone to treat Alzheimer’s disease showed no significant improvement in AS-cog, NPI, and WHOQOL-BREF scores compared to placebo; however, the combined use of غانوديرما لوكيدوم spore powder and memantine showed significant improvement in the three scores compared to memantine alone, إنه, the combined use of غانوديرما لوكيدوم spore powder and memantine can significantly improve the behavioral ability, cognitive ability and quality of life of patients with Alzheimer’s disease.
Currently, the drugs used to treat Alzheimer’s disease, such as donepezil, rivastigmine, memantine, and galantamine (Reminyl), have limited therapeutic effects and can only alleviate symptoms and delay the course of the disease. فضلاً عن ذلك, almost no new drugs for the treatment of Alzheimer’s disease have been successfully developed in the past 20 years. لذلك, the use ofغانوديرما لوكيدوم spore powder to enhance the efficacy of drugs for the treatment of Alzheimer’s disease should be given attention.
As for further clinical trials of using غانوديرما لوكيدوم spore powder alone, it may be possible to consider increasing the dosage, for example, 2000 mg each time, twice a day, for a course of at least 12 weeks. Whether this is feasible, we look forward to research results in this area to tell us the answer.
[مراجع]
1. Guo-hui Wang, وآخرون. Spore powder ofغانوديرما لوكيدوم for the treatment of Alzheimer disease: A pilot study. Medicine（Baltimore）. 2018；97(19): e0636.
2. Wang Lichao, وآخرون. The effect of memantine combined withغانوديرما لوكيدوم spore powder on cognition and quality of life in patients with Alzheimer’s disease. Journal of Armed Police Medical College (Medical Edition). 2019, 28(12): 18-21.
Introduction to Professor Lin Zhibin
Mr. لين زيبين, a pioneer in الجانوديرما research in China, has devoted nearly half a century to the field. He held several positions at Beijing Medical University, including Vice President, Vice Dean of the School of Basic Medicine, Director of the Institute of Basic Medical Sciences, and Director of the Department of Pharmacology. He is now a professor in the Department of Pharmacology at Peking University School of Basic Medical Sciences. From 1983 ل 1984, he was a visiting scholar at the WHO Traditional Medicine Research Center at the University of Illinois at Chicago. From 2000 ل 2002, he was a visiting professor at the University of Hong Kong. Since 2006, he has been an honorary professor at the Perm State Pharmaceutical Academy in Russia.
Since 1970, he has used modern scientific methods to study the pharmacological effects and mechanisms of traditional Chinese medicine الجانوديرما and its active ingredients. He has published over a hundred research papers on Ganoderma. From 2014 ل 2019, he was selected for the Elsevier’s China Highly Cited Researchers List for six consecutive years.
He has written many books on Ganoderma, including “Modern Research on Ganoderma”(1st-4th editions), ”Lingzhi from Mystery to Science”(1st-3rd editions), “Ganoderma supports the healthy energy and dispels pathogenic factors, assisting in the treatment of tumors”, “Discussions on Ganoderma”, and “Ganoderma and Health”.
